Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)
USD 14.17
(-0.14%)
USD 14.17
(-0.14%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.23 Million USD | -84.32% |
| 2022 | 20.65 Million USD | -4.32% |
| 2021 | 21.59 Million USD | -14.05% |
| 2020 | 25.12 Million USD | 210.26% |
| 2019 | 8.09 Million USD | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 375.00 USD | -91.9% |
| 2016 | 4632.00 USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 331.24 Thousand USD | 70892.91% |
| 2012 | 466.59 USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 2.45 Million USD | 0.0% |
| 2024 Q1 | 2.85 Million USD | 0.0% |
| 2023 Q1 | 18.3 Million USD | -11.4% |
| 2023 FY | 3.23 Million USD | -84.32% |
| 2023 Q4 | 3.23 Million USD | -10.3% |
| 2023 Q3 | 3.61 Million USD | -76.39% |
| 2023 Q2 | 15.29 Million USD | -16.45% |
| 2022 Q4 | 20.65 Million USD | 43.54% |
| 2022 Q3 | 14.39 Million USD | -15.06% |
| 2022 Q2 | 16.94 Million USD | -12.57% |
| 2022 Q1 | 19.37 Million USD | -10.25% |
| 2022 FY | 20.65 Million USD | -4.32% |
| 2021 FY | 21.59 Million USD | -14.05% |
| 2021 Q1 | 25.02 Million USD | -0.4% |
| 2021 Q3 | 24.8 Million USD | -0.45% |
| 2021 Q2 | 24.91 Million USD | -0.44% |
| 2021 Q4 | 21.59 Million USD | -12.94% |
| 2020 Q3 | 25.21 Million USD | 231.31% |
| 2020 Q1 | 7.85 Million USD | -2.93% |
| 2020 Q4 | 25.12 Million USD | -0.35% |
| 2020 FY | 25.12 Million USD | 210.26% |
| 2020 Q2 | 7.6 Million USD | -3.19% |
| 2019 FY | 8.09 Million USD | 0.0% |
| 2019 Q4 | 8.09 Million USD | 1.98% |
| 2019 Q3 | 7.94 Million USD | 8.66% |
| 2019 Q2 | 7.3 Million USD | 3.62% |
| 2019 Q1 | 7.05 Million USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | -100.0% |
| 2018 FY | - USD | -100.0% |
| 2017 FY | 375.00 USD | -91.9% |
| 2017 Q4 | 375.00 USD | -74.7% |
| 2017 Q1 | 3609.00 USD | -22.09% |
| 2017 Q3 | 1482.00 USD | -42.09% |
| 2017 Q2 | 2559.00 USD | -29.09% |
| 2016 FY | 4632.00 USD | 0.0% |
| 2016 Q2 | 6277.00 USD | -28.89% |
| 2016 Q1 | 8827.00 USD | 0.0% |
| 2016 Q4 | 4632.00 USD | -12.57% |
| 2016 Q3 | 5298.00 USD | -15.6% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | 211.62 Thousand USD | -36.11% |
| 2014 Q1 | 331.24 Thousand USD | -0.0% |
| 2014 FY | - USD | -100.0% |
| 2014 Q3 | - USD | -100.0% |
| 2013 FY | 331.24 Thousand USD | 70892.91% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | 331.24 Thousand USD | 0.0% |
| 2012 FY | 466.59 USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | 86.712% |
| Dynavax Technologies Corporation | 252.41 Million USD | 98.717% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 90.244% |
| Perrigo Company plc | 3.63 Billion USD | 99.911% |
| Illumina, Inc. | 1.48 Billion USD | 99.782% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.99% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -223.863% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.96% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.975% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 98.136% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.88% |
| Unity Biotechnology, Inc. | 23.53 Million USD | 86.241% |
| Waters Corporation | 2.3 Billion USD | 99.86% |
| Biogen Inc. | 7.18 Billion USD | 99.955% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 90.337% |
| Evolus, Inc. | 120.35 Million USD | 97.309% |
| Adicet Bio, Inc. | 17.7 Million USD | 81.706% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 91.266% |
| bluebird bio, Inc. | 224.41 Million USD | 98.557% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 99.354% |
| FibroGen, Inc. | 89.69 Million USD | 96.389% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.882% |
| Homology Medicines, Inc. | 43.17 Million USD | 92.499% |
| Geron Corporation | 35.05 Million USD | 90.76% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 99.862% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 99.165% |
| Myriad Genetics, Inc. | 130.9 Million USD | 97.526% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -246.008% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 96.652% |
| Zoetis Inc. | 6.56 Billion USD | 99.951% |
| Abeona Therapeutics Inc. | 4.4 Million USD | 26.428% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 99.836% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 99.454% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 99.553% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 90.528% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 99.769% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 92.912% |
| Verastem, Inc. | 40.08 Million USD | 91.921% |
| Nektar Therapeutics | 112.62 Million USD | 97.124% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 98.181% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -5.356% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 99.714% |
| OPKO Health, Inc. | 222.03 Million USD | 98.541% |
| Exelixis, Inc. | 189.94 Million USD | 98.295% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 98.746% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | 97.51% |
| Imunon, Inc. | 1.13 Million USD | -184.267% |
| Blueprint Medicines Corporation | 610.96 Million USD | 99.47% |
| Insmed Incorporated | 1.19 Billion USD | 99.729% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.784% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 94.317% |
| TG Therapeutics, Inc. | 100.11 Million USD | 96.765% |
| Incyte Corporation | 29.16 Million USD | 88.894% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 99.275% |